5 reports

  • CAR-T THERAPY
  • CD19 CAR-T THERAPIES: COMPETITIVE LANDSCAPE

INTRODUCTION Amidst the current initiatives to develop more targeted anti-cancer therapies, chimeric antigen receptor T-cell (CAR-T) therapy has emerged as a potent and viable therapeutic intervention to eradicate tumor cells, with minimal side effects. It is based on the principle of harnessing the innate potential of...

  • Automotive
  • Clinical Trial
  • Motor Vehicle
  • Therapy
  • Novartis AG
  • PATENTS FOR CAR-T FOR SOLID TUMORS
  • MAJOR CAR-T PATENT APPLICANTS

EXECUTIVE SUMMARY CAR-T cell therapy is a remarkably promising treatment for cancer patients. This emerging treatment is the biggest breakthrough since the introduction of chemotherapy. Already two products (Kymriah and Yescarta) have been approved by the U.S. FDA and European EMA for different cancer indications.  What...

  • Cancer
  • Monoclonal Antibody
  • Motor Vehicle
  • Therapy
  • Novartis AG
  • 8. MARKET FORECAST

ONE STEP FORWARD IN THIS DIRECTION WAS THE FIRST HUMAN TRIAL OF AN ANTI-BCMA CAR-T THERAPY.

  • Motor Vehicle
  • Targeted Therapy
  • Therapy
  • Celgene Corporation
  • Novartis AG
  • THERAPIES

CAR-T IS ONE AMONGST A NUMBER OF ADVANCED NOVEL PERSONALIZED IMMUNOTHERAPIES.

  • Lymphoma
  • Monoclonal Antibody
  • Motor Vehicle
  • Therapy
  • Novartis AG
  • T-CELL IMMUNOTHERAPY: MARKET POTENTIAL OF CANDIDATES
  • NOVARTIS: T-CELL IMMUNOTHERAPY COLLABORATIONS

INTRODUCTION WHO has stated that the number of new cancer cases is expected to rise by 70% in the coming two decades.In the US alone, over one million people are diagnosed with cancer each year.Although cancer therapeutics continues to be one of the most active areas in terms of drug development, there is still a significant unmet...

  • Cell Therapy
  • Motor Vehicle
  • Therapy
  • Kite Pharma, Inc.
  • Novartis AG